_256_384.jpg)
News | September 17, 2021
Promising prospects for Indian pharma: CLSA
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
The clinical trial, to be conducted in two phases, will evaluate the safety and efficacy of Mesocel for the treatment of patients with moderate to severe Covid-19
It tests for the presence or absence of ribonucleic acid (RNA) of Dengue (Type 1, 2 4) in serum or plasma from patients suspected of dengue viral infection.
BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
Barbara Engelhardt moves her computational and statistics lab to Gladstone
It will also manage test result documentation for employees who are not vaccinated, sending weekly reminders and employer notification
It comes with a prime focus on infection control and patient flow as the primary infrastructure design aspects - the need of the hour and must-have during a pandemic.
The deal is expected to close in the fourth quarter of 2021 and will enable Roche to further expand the portfolio. TIB Molbiol excels in ultra-rapid assay development of emerging infectious diseases
The amalgamation is expected to bring in a lot of synergies in terms of operational efficiency and productivity for the combined entity
Between 30-40 per cent of Covid-19 patients are either obese or diabetic
Subscribe To Our Newsletter & Stay Updated
